167 related articles for article (PubMed ID: 37591971)
1. Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3.
Rampuria P; Mosyak L; Root AR; Svenson K; Agostino MJ; LaVallie ER
Sci Rep; 2023 Aug; 13(1):13408. PubMed ID: 37591971
[TBL] [Abstract][Full Text] [Related]
2. Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors.
Root AR; Guntas G; Katragadda M; Apgar JR; Narula J; Chang CS; Hanscom S; McKenna M; Wade J; Meade C; Ma W; Guo Y; Liu Y; Duan W; Hendershot C; King AC; Zhang Y; Sousa E; Tam A; Benard S; Yang H; Kelleher K; Jin F; Piche-Nicholas N; Keating SE; Narciandi F; Lawrence-Henderson R; Arai M; Stochaj WR; Svenson K; Mosyak L; Lam K; Francis C; Marquette K; Wroblewska L; Zhu HL; Sheehan AD; LaVallie ER; D'Antona AM; Betts A; King L; Rosfjord E; Cunningham O; Lin L; Sapra P; Tchistiakova L; Mathur D; Bloom L
MAbs; 2021; 13(1):1850395. PubMed ID: 33459147
[TBL] [Abstract][Full Text] [Related]
3. A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.
Mathur D; Root AR; Bugaj-Gaweda B; Bisulco S; Tan X; Fang W; Kearney JC; Lucas J; Guffroy M; Golas J; Rohde CM; Stevens C; Kamperschroer C; Kelleher K; Lawrence-Henderson RF; Upeslacis E; Yao J; Narula J; LaVallie ER; Fernandez DR; Buetow BS; Rosfjord E; Bloom L; King LE; Tchistiakova L; Nguyen A; Sapra P
Clin Cancer Res; 2020 May; 26(9):2188-2202. PubMed ID: 31996389
[TBL] [Abstract][Full Text] [Related]
4. Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C.
Snook AE; Magee MS; Marszalowicz GP; Schulz S; Waldman SA
Cancer Immunol Immunother; 2012 May; 61(5):713-23. PubMed ID: 22057677
[TBL] [Abstract][Full Text] [Related]
5. An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer.
Rappaport JA; Waldman SA
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1125-1137. PubMed ID: 32945718
[No Abstract] [Full Text] [Related]
6. T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C.
Flickinger JC; Singh J; Yarman Y; Carlson RD; Barton JR; Waldman SA; Snook AE
Front Immunol; 2022; 13():855759. PubMed ID: 35355987
[TBL] [Abstract][Full Text] [Related]
7. Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.
Entezari AA; Snook AE; Waldman SA
Expert Opin Ther Targets; 2021 May; 25(5):335-346. PubMed ID: 34056991
[TBL] [Abstract][Full Text] [Related]
8. GUCY2C-targeted cancer immunotherapy: past, present and future.
Snook AE; Magee MS; Waldman SA
Immunol Res; 2011 Dec; 51(2-3):161-9. PubMed ID: 22038530
[TBL] [Abstract][Full Text] [Related]
9. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.
Snook AE; Baybutt TR; Xiang B; Abraham TS; Flickinger JC; Hyslop T; Zhan T; Kraft WK; Sato T; Waldman SA
J Immunother Cancer; 2019 Apr; 7(1):104. PubMed ID: 31010434
[TBL] [Abstract][Full Text] [Related]
10. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evaluation of
Maresca KP; Chen J; Mathur D; Giddabasappa A; Root A; Narula J; King L; Schaer D; Golas J; Kobylarz K; Rosfjord E; Keliher E; Chen L; Ram S; Pickering EH; Hardwick JS; Rejto PA; Hussein A; Ilovich O; Staton K; Wilson I; McCarthy TJ
Mol Imaging Biol; 2021 Dec; 23(6):941-951. PubMed ID: 34143379
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope.
Snook AE; Baybutt TR; Hyslop T; Waldman SA
Hum Gene Ther Methods; 2016 Dec; 27(6):238-250. PubMed ID: 27903079
[TBL] [Abstract][Full Text] [Related]
13. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer.
Gibbons AV; Lin JE; Kim GW; Marszalowicz GP; Li P; Stoecker BA; Blomain ES; Rattan S; Snook AE; Schulz S; Waldman SA
Cancer Res; 2013 Nov; 73(22):6654-66. PubMed ID: 24085786
[TBL] [Abstract][Full Text] [Related]
14. One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics.
Chen W; Yang F; Wang C; Narula J; Pascua E; Ni I; Ding S; Deng X; Chu ML; Pham A; Jiang X; Lindquist KC; Doonan PJ; Van Blarcom T; Yeung YA; Chaparro-Riggers J
MAbs; 2021; 13(1):1871171. PubMed ID: 33557687
[TBL] [Abstract][Full Text] [Related]
15. Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.
Flickinger JC; Rappaport JA; Barton JR; Baybutt TR; Pattison AM; Snook AE; Waldman SA
Biomark Med; 2021 Feb; 15(3):201-217. PubMed ID: 33470843
[TBL] [Abstract][Full Text] [Related]
16. GUCY2C: at the intersection of obesity and cancer.
Kim GW; Lin JE; Waldman SA
Trends Endocrinol Metab; 2013 Apr; 24(4):165-73. PubMed ID: 23375388
[TBL] [Abstract][Full Text] [Related]
17. Targeting the paracrine hormone-dependent guanylate cyclase/cGMP/phosphodiesterases signaling pathway for colorectal cancer prevention.
Yarla NS; Gali H; Pathuri G; Smriti S; Farooqui M; Panneerselvam J; Kumar G; Madka V; Rao CV
Semin Cancer Biol; 2019 Jun; 56():168-174. PubMed ID: 30189250
[TBL] [Abstract][Full Text] [Related]
18. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.
Aka AA; Rappaport JA; Pattison AM; Sato T; Snook AE; Waldman SA
Expert Rev Clin Pharmacol; 2017 May; 10(5):549-557. PubMed ID: 28162021
[TBL] [Abstract][Full Text] [Related]
19. Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.
Qi J; Li X; Peng H; Cook EM; Dadashian EL; Wiestner A; Park H; Rader C
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):E5467-E5476. PubMed ID: 29844189
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity.
Flickinger JC; Singh J; Carlson R; Leong E; Baybutt TR; Barton J; Caparosa E; Pattison A; Rappaport JA; Roh J; Zhan T; Bashir B; Waldman SA; Snook AE
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
